1 in 54 children are diagnosed with autism, with 5.4 million autistic individuals in the U.S. Despite growing spending on autism, there are still limited diagnostic, therapeutic, and service-oriented options for autistic individuals and their families. As a result, stakeholders are left to cope with long wait times, ineffective treatments, and a fragmented care system.
Given a favorable regulatory climate which now requires that payers in all 50 U.S. states provide coverage for ASD diagnosis, treatment, and services, families have an increased ability to access impactful interventions.
At AIF, we are directing capital toward companies that are transforming how autism is diagnosed, treated, and managed.
By investing in early-stage life sciences and life span services companies, we are using venture capital investment as a vehicle for deepening our understanding of autism, establishing a better standard of care, and enabling autistic individuals to reach their full potential.
We hold ourselves accountable to the 75 million people worldwide affected by autism.
Expedite the diagnostic process.
Define ASD with precision.
Identify quantifiable biomarkers.
Integrate data across patients, providers and platforms.
AI x ASD
Leverage the power of AI for ASD.
Develop safe treatments for core symptoms.
Create quality, lifelong educational tools.
Support autistic individuals in achieving independence.
Provide a path to financial security.
Democratize access to care.
Foster innovative partnerships.